Title of Invention	PEPTIDES HAVING AN ACE INHIBITING EFFECT
Abstract	Use of the tripeptide XPP, wherein X= C, M, S, T, or K, and/or salts thereof for the preparation of an angiotensin-converting enzyme inhibitor and food products comprising the tripeptide XPP.

Full Text

F7748 / V FORM - 2 THE PATENTS ACT, 1970 (39 of 1970) & The Patents Rules, 2003 COMPLETE SPECIFICATION (See Section 10 and Rule 13) PEPTIDES HAVING AN ACE INHIBITING EFFECT HINDUSTAN LEVER LIMITED, a company incorporated under the Indian Companies Act, 1913 and having its registered office at Hindustan Lever House, 165/166, Backbay Reclamation, Mumbai -400 020, Maharashtra, India The following specification particularly describes the invention and the manner in which it is to be performed. WO 2005/058070 PCT/EP2004/013223 1 Peptides having an ACE inhibiting effect Field of the invention The invention relates to certain peptides for the 5 preparation of an angiotensin-converting enzyme (ACE) inhibitor. The invention further relates to food products suitable for ACE inhibition and to a process for preparing such food products. 10 Background to the invention Hypertension or high blood pressure is considered to be one of the main risk factors for Cardio Vascular Diseases (CVD) . One of the mechanisms which regulates blood pressure is the renin-angiotensin system. This is a cascade of 15 reactions leading to the formation of angiotensin II, which has a strong vasoconstrictive and hence blood pressure increasing effect. Inhibition of one of the key. enzymes in this cascade: Angiotensin I Converting Enzyme (ACE) reduces formation of angiotensin II and thus has a blood pressure 20 lowering effect. Long term human intervention studies have shown regular intake of low amounts of ACE inhibitors reduces CVD by 25% (Gerstein et al. (2000) , The Lancet 355, 253-259). 25 ACE-inhibitors in food products are well known. Such food products have for instance been prepared t>y fermentation of milk or milk products. In a placebo-controlled study, the blood pressure lowering effect of VPP and IPP in sour milk was shown in hypertensive humans (Hata, Y et al. (1996), 30 American Journal of Clinical Nutrition 64r 767-771) . WO 2005/058070 PCT/EP2004/013223 2 A commercially available fermented milk product, which claims to be "suitable for those with mild hypertension" is Calpis sour milk, fermented with Lactobacillus helveticus, produced by Calpis Food Industry, Japan. Another 5 commercially available fermented milk product is Evolus produced by Valio, Finland, which claims to be "'the first European functional food to help lower blood pressure'. These fermented milk products are fermented with Lactobacillus helveticus (Lb. helveticus) strains. The 10 products contain bio-active peptides (VPP and IPP) responsible for in vitro ACE inhibition, which are produced by proteolysis of caseins. Another possibility identified in the prior art is 15 preparation of ACE-inhibiting food products by enzymatic hydrolysis of milk proteins. WO 01/85984 describes the preparation of an ACE-suppressing composition by hydrolysis of casein isolate using the enzyme trypsin. 20 Summary of the invention It is an object of the invention to provide a food product suitable for ACE inhibition. It is another object to provide such food products having blood pressure lowering effect. It is still a further object to provided food 25 product having a high concentration of ACE-inhibitor. One or more of these objects is attained according to the invention by the use of the tripeptide XPP, wherein X= C, M, S, T, or K and/or the salts thereof for the preparation of an angiotensin-converting enzyme inhibitor. 30 WO 2005/058070 PCT/EP2004/013223 3 Detailed description of the invention The common one letter code is used herein as ordinarily used to describe amino-acids. The weight percentages herein will be expressed, relative to 5 the total weight, unless otherwise indicated. Enzyme is herein understood to also include a mixture of more than one enzymes. 10 According to the invention, we have found that the tripeptide XPP according to the invention is relatively stable after human consumption and that the peptide XPP according to the invention is an effective angiotensin-converting enzyme inhibitor. Preferably the angiotensin- 15 converting enzyme inhibitor is a functional food product. In XPP, X= C, M, S, T, or K. Preferably X= C, M, S, or T, more preferably X= M, S, or T. 20 The invention provides a food product suitable for angiotensin-converting enzyme inhibition and lowering of blood pressure in humans comprising an amount 1 mg/g or more of XPP, wherein X= C, M, S, T, or K, preferably 25mg/g or more of XPP, more preferably the food product comprises 25 an amount of 50 mg/g or more, even more preferably 100 mg/g or more XPP, wherein X= C, M, S, T, or K, preferably X= C, M, S, or T, more preferably X= M, S, or T. Food products according to the invention are defined as 30 products, suitable for human consumption, in which an XPP according to the invention was used as an ingredient in an WO 2005/058070 PCT/EP2004/013223 4 effective amount, such that a noticeable ACE-inhibitory effect is obtained. Though not wishing to be bound to theory herein, it is 5 believed that the tripeptides according to the invention are good ACE-inhibitors, since they are: • relatively small in size [length between 2 and 10 amino acids] 10 • neutral or positively charged • not composed of negatively charged residues • composed of hydrophobic, branched amino acids • have a C-terminal Proline residue 15 Further it is believed that to the presence of two successive Pro-residues, the release of the last two residues by ACE in the case of XPP is significantly hindered due to steric constraints. 20 Additionally it is believed that the presence or the C- terminal PP (-Pro-Pro) sequence renders the peptide(s) more stable towards human digestive enzymes, peptidases associated with brush-border membrane of the human intestinal epithelium cells and peptidases in the human 25 blood circulation. Therefore, it is believed that the consumption of a food product containing the peptide(s) will result in the effective absorption of the peptide(s) in the human body, which will induce ACE-inhibition and lowering of blood pressure. 30 WO 2005/058070 PCT/EP2004/013223 5 Summarising these observations it can be deduced that any peptide that that is not too long and composed of hydrophobic amino acids, neutral or positively charged and bearing a C-terminal Pro [or-Pro-Pro] sequence is 5 intrinsically a good inhibitor for ACE. In general the results are in agreement with the observations, the best ACE-inhibiting XPP-peptides are composed of neutral and hydrophobic amino acids. The reason 10 that large hydrophobic residues like Trp, Tyr and Phe are not included resides from the fact that - most likely -these residues, in combination with the two Pro residues, are too bulky for a proper fit in the active site of the enzyme. 15 The reason that CPP is included derives from the fact that ACE is a Zn-containing enzyme and interaction of the substrate with the Zn-atom is essential for binding between substrate and enzyme, the presence of the free sulphydryl- 20 group of Cys favors this interaction. The following proteins (and their precursors) have, for example, been identified to contain mentioned XPP sequences within the primary structure of their constitutional 25 proteins and their sources: CPP: collagen [chicken], troponin [chicken], thyroglobin [bovine] MPP: albumin [garden pea, mung bean], myosin [bovine, 30 chicken, pig, yeast], zein [maize] SPP: collagen [chicken], casein [bovine], legumin [garden pea, Pea Sativum]. WO 2005/058070 PCT/EP2004/013223 6 TPP; collagen [chicken], glutenin [wheat], cruceferin [rape], legumin [cotton], myosin [yeast], zein [maize] TPP: collagen [chicken], glutenin [wheat], cruceferin [rape], legumin [cotton], myosin [yeast], zein [maize] 5 KPP: myosin [pig, chicken, yeast], casein [pig] These protein materials may, for instance be used as a substrate, from which the peptides according to the invention may be liberated. The skilled person will know to 10 use known fermentation or known enzyme treatment, for instance enzymatic hydrolysis to achieve this. Through optimization of the fermentation or hydrolysis conditions, the production of the biologically active 15 molecule XPP according to the invention may be maximized. The skilled person trying to maximize the production will know how to adjust the process parameters, such as hydrolysis time, hydrolysis temperature, enzyme type and concentration etc. 20 Preferably, in the production of the XPP, the molar yield of XPP is high. The molar yield of XPP is defined as the molar amount of XPP produced divided by the molar amount of XPP fragments in the total mass of protein present in the 25 starting material prior to hydrolysis. The enzyme used in enzymatic hydrolysis may be any enzyme that is able to effectively hydrolyze a substrate containing XPP, resulting in the liberation of one or more 30 XPP, wherein X= C, M, S, T, or K. WO 2005/058070 PCT/EP2004/013223 7 The enzyme treatment may be done in a conventional manner. It involves adding enzyme (or a mixture of enzymes) to the substrate and maintaining the resulting reaction mixture under controlled conditions suitable for conducting the 5 enzymatic hydrolysis. The conditions to be controlled include temperature, pH, reaction time and enzyme concentration. The preferred temperature of the reaction mixture is 40-60 degrees C, more preferred 45-55 degrees C and most preferred about 50 degrees C. The pH of the 10 reaction mixture is preferably 5 to 9, more preferably 6-8 and most preferably about 7. The enzyme concentration is 2-10 wt.% based on the total weight of the reaction mixture, more preferably 3-10 and most preferably 4-6 wt%. The reaction time (hydrolysis time) is preferably 2-50 hours, 15 more preferably 2- 10 hours and most preferably-4-8 hours. In another preferred embodiment the hydrolysis step may be substituted by a fermentation step with microorganism that will cause hydrolysis of the substrate. 20 The materials in the fermentor and substrate may be mixed in conventional way, in order to achieve a homogeneous fermentation medium. 25 The fermentation advantageously may be performed at 25 to 50° C and preferably 35 to 45° C, for 3 to 80 hours and preferably 6 to 25 hours. Advantageously, after enzyme treatment and optional 30 fermentation, several additional process steps may be executed. WO 2005/058070 PCT/EP2004/013223 8 : Preferably according to the invention a process for the preparation of a food product comprising XPP, wherein X= C, M, S, T, or K, involving the following steps is used: 5 a)enzymatic hydrolysis of a substrate comprising protein having the sequence XPP, resulting in a hydrolyzed protein product; b)separation from the hydrolyzed protein product of a 10 fraction rich in tripeptide; c)drying the fraction from step b) to obtain a solid rich in tripeptide XPP; 15 d)using the solid prepared in step c) as an ingredient in the preparation of the food product. After the enzymatic hydrolysis step a), therefore there may be an optional separation step or concentration step. This 20 step may be executed in any way known to the skilled person, e.g. by filtration,. centrifugation or chromatography and combinations thereof. Preferably the separation step is executed using an ultrafiltration (UF) and/or nanofiltration (NF) techniques. The pore size of the 25 membranes used in the filtration step, as well as the charge of the membrane may be used to control the separation of the tripeptide XPP. The fractionation of protein hydrolysates using charged UF/NF membranes is described in Y. Poilot et al, Journal of Membrane Science 30 158 (1999) 105-114. Electrodialysis is for instance described in WO00/42066. The product of such separation step is herein called the ACE-fraction. WO 2005/058070 PCT/EP2004/013223 9 Optionally the hydrolysis product may be dried, to obtain a solid rich in tripeptide XPP, wherein X= C, M, S, T, or K. This step may be done in a conventional way, e.g. by spray 5 drying or freeze drying. The dried product prepared in is hereafter designated as ACE-solid. The ACE-fraction and/or the ACE-solid may advantageously be used as an ingredient in a food product. 10 The food product according to the invention or food products derived there from may be pasteurised or sterilised. 15 The food products according to the invention may be of any food type. They may comprise common food ingredients in addition to the food product, such as flavor, sugar, fruits, minerals, vitamins, stabilisers, thickeners, etc. in appropriate amounts. 20 Preferably, the food product comprises 50-200 mmol/kg K+ and/or 15-60 mmol/kg Ca2+ and/or 6-25 mmol/kg Mg2+ more preferably, 100-150 mmol/kg K+ and/or 30-50 mmol/kg Ca2+ and/or 10-25 mmol/kg Mg2+ and most preferably 110-135 25 mmol/kg K+ and/or 35-45 mmol/kg Ca2+ and/or 13-20 mmol/kg Mg2+. Preferably the food products are fruit juice products, dairy type products, frozen confectionary products or 30 spreads/margarines. These preferred types of food products are described in some detail below and in the examples. WO 2005/058070 PCT/EP2004/013223 10 • Fruit juice products Examples of fruit juice products according to the invention are juices derived from citrus fruit like orange and grapefruit, tropical fruits, banana, peach, peer, 5 strawberry, to which ACE-solids and/or ACE-fraction are added. • Dairy type products Examples of dairy products according to the invention are 10 milk, dairy spreads, cream cheese, milk type drinks and yoghurt, to which ACE-solids and/or ACE-fraction are added or in which XPP is produced during preparation of the food product. The food product may be used as such as a milk type drink. Alternatively or additionally flavor or other 15 additives may be added. A dairy type product may also be made by adding ACE-solids and/or ACE-fraction to water or to a dairy product. An example of a composition for a yoghurt type product is about 50-80 wt. % water, 0.1-15 wt. % ACE-solids, 0-15 wt.% 20 whey powder, 0-15 wt.% sugar (e.g. sucrose), 0.01-1 wt.% yoghurt culture, 0-20 wt.% fruit, 0.05-5 wt.% vitamins and minerals, 0-2 wt.% flavor, 0-5 wt.% stabilizer (thickener or gelling agent). 25 A typical serving size for a yoghurt type product could be from 50 to 250 g, generally from 80 to 200 g. • Frozen Confectionery Products For the purpose of the invention the term frozen 30 confectionery product includes milk containing frozen confections such as ice-cream, frozen yoghurt, sherbet, WO 2005/058070 PCT/EP2004/013223 11 sorbet, ice milk and frozen custard, water-ices,, granitas and frozen fruit purees. Preferably the level of solids in the frozen confection 5 (e.g. sugar, fat, flavouring etc) is more than 3: wt.%, more preferred from 10 to 70 wt.%, for example 40 to 70 wt.%. Ice cream will typically comprise 0 to 20 wt.% of fat, 0.1 to 20 wt.% ACE-solids, sweeteners, 0 to 10 wt.% of non-fat 10 milk components and optional components such as emulsifiers, stabilisers, preservatives, flavouring ingredients, vitamins, minerals, etc, the balance being water. Typically ice cream will be aerated e.g. to an overrun of 20 to 400 %, more specific 40 to 200 % and frozen to a temperature of 15 from -2 to -200 °C, more specific -10 to -30 °C. Ice cream normally comprises calcium at a level of about 0.1 wt%. • Other food products Other food product according to the invention can be 20 prepared by the skilled person based on common general knowledge, using hydrolysed protein as a base material for food or using derived products, such as ACE-solids as an ingredient in suitable amounts. Examples of such food products are baked goods, dairy type foods, snacks, etc. 25 Advantageously the food product is an oil and water containing emulsion, for instance a spread. Oil and water emulsion is herein defined as an emulsion comprising oil and water and includes oil in water (0/W) emulsions and 30 water in oil emulsions (W/O) and more complex emulsions for instance water-in-oil-in-water (W/O/W/O/W) emulsions. Oil is herein defined as including fat. Preferably the food WO 2005/058070 PCT/EP2004/013223 12 product is a spread, frozen confection, or sauce. Preferably a spread according to the invention comprises 30-90 wt.% vegetable oil. Advantageously a spread has a pH of 4.2-6.0. WO 2005/058070 PCT/EP2004/013223 13 Examples Example 1 A large number of peptides were screened for their ACE- 5 inhibiting effects (IC50 values were measured). In addition all peptides were screened for stability during exposure to human serum, HUVEC, Caco-2 cells and gastrointestinal enzymes as described below. 10 The materials and methods used in Example 1 are described below. Cell culture Caco-2 cells were obtained from American Type Culture 15 Collection (ATCC) and used in experiments at passage 30-40. Cells were cultured in 75 cm2 culture flasks (Corning Costar, Badhoevedorp, The Netherlands). The culture medium consisted of DMEM (high glucose, with L-glutamine) supplemented with 20% (v/v) foetal bovine serum, 1% (v/v) 20 penicillin/streptomycin solution and 1% (v/v) NEAA. Cells were maintained at 37° C in a humidified atmosphere of 5% CO2 in air. For stability experiments, cells were seeded on 12 well cell culture plates (Costar, Badhoevedorp, The Netherlands) and cultured for at least 21 days. 25 HUVEC Cells HUVEC cells were obtained from (Cambrex Bio Science, Verviers, Belgium) and used in experiments at passage 1-5. Cells were cultured in 75 cm2 culture flasks (Corning 30 Costar, Badhoevedorp, The Netherlands). The culture medium (Cambrex) consisted of EBM-2 supplemented with 2% (v/v) foetal bovine serum, 0.04 % (v/v) Hydrocortisone, 0.4 % WO 2005/058070 PCT/EP2004/013223 14 (v/v) human Fibroblast Growth Factor Basic with heparin, 0.1 % (v/v) Vascular Endothelial Growth Factor, 0.1 % (v/v) human recombinant Insulin-like Growth Factor, 0.1 % (v/v) Ascorbic acid, 0,1 % (v/v) human recombinant Epidermal 5 Growth Factor, 0.1 % (v/v) Gentamicin, Amphotericin-B and 0.1% (v/v) Heparin. Cells were maintained at 37° C in a humidified atmosphere of 5% CO2 in air. For stability experiments, cells were seeded in a 12 well plate (Corning Costar, Badhoevedorp, The Netherlands) at a density of 10 100.000 cells/well and cultured for 2 days. Test products Peptide mixture 1 consisted of VPP, IPP, IIAEK, ITP, VF, FY, KVLPVP, and HLPLP. ^Mixture 2 consisted of VAP, GPR, 15 CPP, MPP, SPP, TPP, PIP, and PLP. The synthetic peptides were either ordered from Bachem (dipeptides KPP and GPR) or from the University of Utrecht (Dr. M. Egmond). The peptides were dissolved separately in a concentration 20 of 5 mg in 50 pi milliQ water or DMSO. For some peptides the concentration was corrected for purity (ITP 60%, KVLPVP 85%). The remaining peptides were >95% pure. All peptides were dissolved in milli Q water except for the dipeptides. FY was dissolved in DMSO. Since FY was still not soluble 25 some HCl (final concentration 0.3M) was added. VF was directly dissolved in 0.3M HCl. To prepare mixture 1, 50 µl of each peptide were mixed together and 100 pi milli Q water was added, yielding a 500 pi solution containing 5 mg of each peptide (in 0.06M HCl and 10% DMSO). Mixture 2 was 30 prepared in the same way, with the exception of- the addition of an extra 50 pi milli Q water. The final composition of mixture 2 was also l0mg/ml of each peptide. WO 2005/058070 PCT/EP2004/013223 15 Stability tests of peptides Stability tests with serum, HUVEC and Caco-2 cells Peptide mixtures were added to human serum (Cambrex Bio 5 Science, Verviers, Belgium) at a final concentration of 0,1 1 and 10 pg peptide/L. Serum containing the peptide-mixtures were incubated for 0, 1, 2, 5, 10, 20, 60, 120, 240 and 360 minutes at 37° C. Samples of 1.5 ml were collected in eppendorf vials at each of the time points. 10 Immediately thereafter, 30 pi of 10% (v/v) trifluoro acetic acid (TFA) and 5 µl of a 10 pg UC13-IPP/10 ml were added to the samples. Samples were subsequently incubated for 5 min at 100° C and then centrifugated in an IEC Micromax RF centrifuge (Boom BV Meppel) at 10.000 rpm for 20 minutes. 15 The supernatant was collected in eppendorf vials and stored at -20°C for further analysis. Experiments were performed in triplicate. Cells were cultured in 12-well plates. Peptide mixtures 20 were added to culture medium without foetal bovine serum, but containing 20 % (v/v) solid phase extracted foetal bovine serum. For HUVEC, 400 pi medium containing 0.1, 1 and 10 pg/ml peptide was added to a well of the culture plate. Three times 130 pi medium was collected at 0, 5, 10, 25 20, 30, 60, 90 and 120 min of incubation. For Caco-2 cells, 330 pi medium containing 0.1, 1 and 10 pg/ml peptide was added to each well of the culture plate. Three times 110 pi medium was collected at 0, 5, 10, 20, 30, 60, 90, 180 and 360 min of incubation. Experiments were performed in 30 triplicate and all samples were directly placed-on dry-ice and stored at - 20°C. For peptide quantification measurement, TFA and UC13-IPP (final concentrations of 0.2% WO 2005/058070 PCT/EP2004/013223 16 (v/v) and 60 ng/ml, respectively) were added to the samples. Wells without cells served as controls. ACE-inhibition assay 1: Enzyme based Assay (EBA) 5 ACE and a synthetic substrate (Abz-FRK-(Dnp)P-OH) were used in the ACE-inhibition assay performed in white optiplate-96 microplates (Packard Bioscience). The substrate was a kind gift of Adriana K. Carmona (Dept. of Biophysics, Escola Paulista de Medivina, Universidae Federal de Sao Paulo, 10 Brazil). Stock solutions of Abz-FRK-(Dnp)P-OH were prepared in DMSO. The concentration was measured spectrophotometrically using the molar extinction coefficient S365 = 17300 M^crrf1. The assay buffer composition was 100 mM tris/HCl buffer pH 7.0 containing 15 100 mM NaCl. Forty pi sample solution in assay buffer was added to each well. In case of the controls only buffer was added. The samples were measured in threefold in a fluorophotometer (Fluostar, BMG labtechnologies). The device first dispersed 150pl substrate (3.75 µM in assay 20 buffer) and subsequently added 20ul of ACE (0.00625 Units/ml) to each well. The ACE activity was measured for 10 cycles (about 10 minutes) by measuring the fluorescence at λex = 320nm and Xem - 420nm. The raw data was converted to the slope/sec and the ACE inhibition activity was 25 calculated using the equation below. WO 2005/058070 PCT/EP2004/013223 ACE inhibition (%) = [1 - (Smean - Bmean) / (Cmean - Bmean )] *100 Where 5 Smean = average result of sample (peptide + substrate + ACE) Bmean = average result of background (substrate) Cmean = average result of control (ACE + substrate) ACE-inhibition assay 2: Modified Matsui assay 10 This ACE inhibition activity was assayed according to the method of Matsui et al. (Matsui, T. et al. (1992) Biosci. Biotech. Biochem. 56: 517-518) with the modifications described below. 15 Table 1: procedure for Matsui ACE inhibition assay. The components were added in a 1.5-ml tube with a final volume of 120 µl. Component Control 1 Control 2 Sample 1 Sample 2 (µl) (µl) (µl) (µl) HHL (3 mM) 75 75 75 75 H20 25 45 - 20 Sample/inhibit - - 25 25 or ACE (0.1 U/ml) 20 - 20 - 20 For each sample 75 µl 3 mM hippuryl histidine leucine (Hip-His-Leu, Sigma chemicals Co.; the chemical was dissolved in 250 mM Borate containing 200 mM NaCl, pH 8.3); 20 pi 0.1 U/ml ACE (obtained at Sigma) or H20, and 25 pi sample or H20 were mixed (see Table 1). The mixtures were incubated 25 at 37°C and stopped after 30 min by adding 125 µl 0.5 M HC1. Subsequently, 225 pi bicine/NaOH solution (1 M NaOH : WO 2005/058070 PCT/EP2004/013223 18 0.25 M bicine (4:6)) was added, followed by 25 µl 0.1 M TNBS (2,4,6-Trinitrobenzenesulfonic acid, Fluka, Switzerland; in 0.1 M Na2HP04) . After incubation for 20 min. at'37°C, 4 ml 4 mM Na2S03 in 0.2 M NaH2P04 was added 5 and the absorbance at 416 nm was measured with UV/Vis spectrophotometer (Shimadzu UV-1601 with a CPS controller, Netherlands). The amount of ACE inhibition (ACEI) activity was calculated as a percentage of inhibition compared with the-conversion 10 rate of ACE in the absence of an inhibitor: ACEI (%) = (((C1-C2)-(S1-S2))/(C1-C2)) * 100 (1) wherein 15 CI = Absorbance without ACE inhibitory component (= max. ACE activity) [AU]. C2 = Absorbance without ACE inhibitory component and without ACE (background) [AU] . S1 = Absorbance in the presence of ACE and the ACE 20 inhibitory component [AU] . S2= Absorbance in the presence of the ACE inhibitory component, but without ACE [AU]. Quantification of peptides using HPLC-MRM-MS 25 All measurements were carried out on a Waters Quattro-II or Quattro-Ultima triple quadrapole mass spectrometer. The LC separation was carried out at 25° C on a Inertsil 5 ODS3 column, 150 x 2.1 mm, packed with 3 urn particles (Chompack) using 0-50% acetonitrile/ 0.1% (v/v) TFA. For analyses, 5 30 µl sample was injected onto the column. The flow rate through the column was 0.2 ml/min. The total flow after post-column makeup was 0.05 ml/min and contained a 7/3 WO 2005/058070 PCT/EP2004/013223 19 (v/v) mixture of propionic acid and propanol-2. • Gradient effluent was analysed using MRM mass spectrometry in positive-ESI mode. Capillary voltage was 4 kV :Source and nebulizer temperature were 100 °C and 250 °C, repsectively 5 Drying and nebuliser gas flow were 300 1/h and 17 1/h, respectively. Collision gas was argon at a pressure of 7.9 e-4 mbar. The MS-data for the analysed peptides are given in table 2. WO 2005/058070 PCT/EP2004/013223 20 Table 2: Description of the MS-parameters for the selected peptides. Peptide Precursor ion Cone voltage Product ion.Massstructure Collision energy VPP 312.2 19 213.1 PP 18 IPP 326.2 19 213.1 PP 18 ITP 330.2 16 116.1 P 11 IIAEK - 573.4 40 347.2 AEK 26 MPP 344.2 19 213.1 PP : 21 SPP 300.2 18 185.1 SP 14 TPP 314.2 18 199.1 TP 16 GPR 329.2 23 175.1 PR . 25 PIP 326.2 16 211.1 IP 13 PLP 326.2 16 211.1 LP 13 VF 265.1 18 72.0 V 15 FY 329.1 23 120.1 F 18 HLPLP 576.3 25 251.2 HL 20 KVLPVP 652.4 36 341.3 KVL. 24 VAP 286.2 15 116.1 P ; 13 In vitro gastrointestinal digestion 5 The stability of peptides in the human gastrointestinal tract was studied by subjecting fermented or hydrolysed milk proteins to typical conditions in the stomach and small intestine. Gastric conditions were mimicked by dissolving 80 ml fermented or hydrolysed milk protein in 10 820 ml water containing 2.0 g NaCl, 2.9 g pepsin and 0.45 g Amano Lipase F-AP15 from Rhizopus oryzae. The fluid was adjusted to pH 3.5 with HC1, stirred with a peddle (50 rpm) and kept at 37° C for 60 min. Subsequently, intestinal conditions were mimicked by adding 9 g pancreatin and 125 WO 2005/058070 PCT/EP2004/013223 21 mg bile-extract to the simulated gastric fluid and adjusting the pH to 6.8 with NaHC03. The simulated intestinal fluid was stirred with a peddle (50 rpm) and kept at 37° C for 120 min. Samples were collected at 5 different time points during the in vitro gastrointestinal digestion. After collection, samples were directly heated at 95° C for 30 min and subsequently stored at -20° C. The results of example 1 are given in table 3. WO 2005/058070 PCT/EP2004/013223 22 Table 3: Stability of peptides during exposure to human serum, HUVEC, Caco-2 cells and gastrointestinal proteases (GI conditions) as determined by LC-MS. Peptide { Serum HUVEC Caco-2 GI conditions ICJOMatsui(µM) IC50 EBA (µM) VPP + /- + - + 3 20 IPP + /- + - + 2 12 ITP - - - ND 10 30 IIAEK - - - + /- >20 20 VF + /- - + /" ND 10 >100 FY + - +/- ND 10 20 HLPLP + /- + + + 17 15 KVLPVP - - - ND 2 5 VAP - - - ND 1 4 GPR - + - ND ND ND KPP ND ND ND ND 50 >50 CPP ND ND ND ND 4 5 MPP +/- + - ND 7 10 SPP +/- + + ND >50 75 TPP +/- + + ND 15 35 PIP - +/- - ND ND >50 PLP - +/- - ND ND >50 Explanation of signs used in table 3: + = stable 10 - = fast degradation by cells or serum: +/- = slow degradation by cells or serum ND = not determined 15 Table 3 shows that all XPP's wherein X= C, M, S, T, or K are moderate to good ACE-inhibitors (low IC50 values). Further these peptides show, compared to other peptides tested, slow degradation when subjected to human serum and WO 2005/058070 PCT/EP2004/013223 23 they are relatively stable when subjected to HUVEC, Caco-2 and gastrointestinal enzymes. WO 2005/058070 PCT/EP2004/013223 24 Claims 1. Use of the tripeptide XPP, wherein X= C, M,.S, T, or K and/or salts thereof for the preparation of an angiotensin-converting enzyme inhibitor. 2. Use according to claim 1, wherein the tripeptide is XPP, wherein X= C, M, S, or T. 3. Use according to claim 2, wherein the tripeptide is XPP, wherein X= M, S, or T. 4. Use according to any of claims 1-3, wherein the angiotensin-converting enzyme inhibitor is a functional food product. 5. Food product suitable for lowering blood pressure in humans comprising an amount" of 5 mg/g or more of XPP, wherein X=C, M, S, T, K, P or A. 6. Food product according to claim 5, wherein the amount of XPP is l0mg/g or more. 7. Food product according to claim 5 or 6, wherein the XPP is XPP, wherein X= C, M, S, or T. 8. Food product according to claim 7, wherein the XPP is XPP, wherein X= M, S, or T. 9. Process for the preparation of a food product comprising XPP, wherein X= C, M, S, T, or K, involving the following steps: WO 2005/058070 PCT/EP2004/013223 25 a) enzymatic hydrolysis of a substrate comprising protein having the sequence XPP, resulting in a hydrolysed protein product; b) separation from the hydrolysed protein product of a fraction rich in tripeptide; c) drying the fraction from step b) to obtain a solid rich in tripeptide XPP; d) using the solid prepared in step c) as an Ingredient in the preparation of the food product. Dated this 12th day of June 2006 HINDUSTAN LEVER LIMITED (S. Venkatramani) Sr Patents Manager

Documents:

683-mumnp-2006-cancelled pages-(12-6-2006).pdf

683-mumnp-2006-claims(granted)-(12-6-2006).doc

683-mumnp-2006-claims(granted)-(12-6-2006).pdf

683-mumnp-2006-claims.doc

683-mumnp-2006-claims0033.pdf

683-mumnp-2006-claims0034.pdf

683-mumnp-2006-correspondance-received.pdf

683-mumnp-2006-correspondence(ipo)-(25-2-2008).pdf

683-mumnp-2006-correspondence1(27-10-2006).pdf

683-mumnp-2006-correspondence2(11-4-2008).pdf

683-mumnp-2006-description (complete).pdf

683-mumnp-2006-form 1(12-6-2006).pdf

683-mumnp-2006-form 1(26-7-2007).pdf

683-mumnp-2006-form 13(26-7-2007).pdf

683-mumnp-2006-form 13(8-2-2007).pdf

683-mumnp-2006-form 18(27-10-2006).pdf

683-mumnp-2006-form 2(granted)-(12-6-2006).doc

683-mumnp-2006-form 2(granted)-(12-6-2006).pdf

683-mumnp-2006-form 5(12-6-2006).pdf

683-mumnp-2006-form-1.pdf

683-mumnp-2006-form-2.doc

683-mumnp-2006-form-2.pdf

683-mumnp-2006-form-3.pdf

683-mumnp-2006-form-5.pdf

683-mumnp-2006-form-pct-isa-210(12-6-2006).pdf

683-mumnp-2006-power of attorney(13-12-2006).pdf